Patients with NHL and two or three factors of the International Prognostic Index (IPI) have a poor prognosis. We performed a prospective trial of intensive induction therapy followed with high-dose consolidation in such patients to determine the feasibility of this approach, as well as the response rate and survival. Untreated patients with aggressive lymphoma under the age of 60 with two or three adverse prognostic factors (disseminated stage, increased serum LDH, ECOG performance status Ͼ1) were prospectively included between June 1995 and April 1998 in a trial evaluating intensive induction chemotherapy with the ACE regimen (adriamycin day 1; cyclophosphamide days 1-2; etoposide days 1-3), with G-CSF support. Patients in complete remission after induction received one course of intensification with stem cell support (BEAM regimen), whereas patients in partial response received two intensifications (BEAM, then ICE regimens). Thirty-three patients (median age 38 years) were included. All patients presented WHO grade 4 leukopenia and 84% grade 3-4 thrombocytopenia during induction. There was one toxic death during induction. Twenty-nine patients proceeded to high-dose consolidation, including 12 patients who received a second high-dose treatment. The overall response rate was 88% (95% CI 76-99%), both after induction therapy and treatment completion. Thirty-nine percent of the patients had achieved complete remission after induction, and 73% after treatment completion. With a median follow-up after treatment onset of 29 months, the projected 3-year overall survival was 71% (95% CI 64-78%) and the event-free survival 58% (95% CI 50-66%). Event-free survival was significantly shorter in patients who did not achieve CR after induction therapy or after treatment completion. Early therapeutic intensification after intensive induction chemotherapy is feasible in patients with poor prognosis aggressive NHL and shows promising response and survival rates. Leukemia (2000) 14, 2159-2165.
Introduction
The age-adjusted International Prognostic Index (IPI) 1 for patients under the age of 60 with aggressive non-Hodgkin's lymphoma (NHL) defines subgroups with various prognoses. Patients with two or three adverse prognostic factors (disseminated stage, altered performance status and/or increased serum lactic dehydrogenase) have a poor prognosis, with a 5-year overall survival of 39%. A variety of clinical and biological prognostic factors have been described, but the IPI is currently the most widely used prognostic system.The optimal treatment of high risk patients with aggressive NHL has not yet been defined. The International Consensus Conference which convened in 1998 concluded that the available evidence did not yet support the use of first-line high-dose ther- apy in NHL patients, even in a subgroup selected for poor prognostic factors. 2 The randomized prospective LNH 93 trial showed a more favorable outcome in high risk patients treated conventionally than in patients receiving high-dose therapy. 3 On the other hand, retrospective studies or subgroup analyses of prospective studies suggest that therapeutic intensification of chemoresponsive patients allows better prognosis in selected patients. 4, 5 One possibility may thus be that high-dose therapy may provide benefit to high-risk patients insofar as the induction therapy has been optimized.
The aim of this study was to improve the antitumor efficacy of induction chemotherapy prior to high-dose therapy by focusing on a limited number of highly effective antimitotic compounds. Dose intensity was achieved during induction by administering high doses of three chemotherapeutic agents, doxorubicin, cyclophosphamide and etoposide, over a short period of time, with alternate escalation of the doses of cyclophosphamide and etoposide. We report the results on 33 young high risk patients who were treated in our center between 1995 and 1998. This subgroup of patients was defined by a diagnosis of aggressive NHL and the presence of two or three factors of the age-adjusted IPI (stage, performance status, serum LDH).
Patients and methods

Patients
Thirty-three patients with newly diagnosed aggressive lymphoma were included between June 1995 and April 1998 in a prospective phase II trial evaluating intensive induction therapy with high-dose consolidation in chemosensitive patients. Inclusion criteria included: diagnosis of aggressive lymphoma (diffuse large cell, anaplastic, lymphoblastic, Burkitt cell, peripheral T cell subtypes); no prior treatment; normal ventricular ejection fraction; presence of two or three adverse prognostic factors (stage 3 or 4, performance status Ͼ1, increased serum LDH); presence of evaluable or measurable tumor mass; age Ͻ60 years. This protocol was approved by the local Protocol Review Committee and patients gave written informed consent.
Disease was evaluated at diagnosis, after induction, after intensification and 2 months after the last course of treatment. Evaluation at diagnosis included CAT scans of the thorax, abdomen and pelvis, bone marrow biopsy and smear, cytological analysis of CSF, serum levels of LDH and beta 2 microglobulin, electrophoresis of serum proteins. Complete response (CR) was defined as the disappearance of all sign of disease. Partial response (PR) was defined as the a reduction of at least 50% of all localizations of disease. Progressive disease (PD) was defined by the appearance of a new localization of disease or an increase in size of at least 25% of one of the previously identified localizations. Residual masses/very good responses (VG) were defined by lesions measuring less than 10% of the initial disease localizations in case of bulky disease.
Treatment Induction chemotherapy:
Patients were due to receive up to three courses of ACE (adriamycin, cyclophosphamide, etoposide) in order to reach optimal response. Individual patients were included at different dose levels, and received all courses at the same doses. At least nine patients were included at each dose level. Adriamycin was administered at 75 mg/m 2 on day 1 at all levels, with no dose escalation in order to avoid excessive acute toxicity such as mucositis. Cyclophosphamide was administered on days 1 and 2, at 1 g/m 2 /day at level 1 and at 1.2 g/m 2 /day at levels 2 and 3. Etoposide was administered on days 1, 2 and 3, at 150 mg/m 2 /day at levels 1 and 2 and at 180 mg/m 2 /day at level 3. Courses were planned to be administered every 2 weeks with hematopoietic growth factor support.
Intensification procedure:
Patients in complete response after induction chemotherapy received one intensive treatment (BEAM). Patients in partial response after induction chemotherapy received two intensive treatments (BEAM, then ICE). Peripheral blood stem cells were collected after the second course and, if necessary, after the third course of ACE. A minimum of 4 × 10 6 CD34 + cells/kg were collected for each intensification procedure. The first intensification was planned to be administered 4 weeks after the last course of induction chemotherapy and consisted of BEAM (BCNU 300 mg/m 2 , day 1), etoposide (400 mg/m 2 , days 2-5), aracytine (400 mg/m 2 , days 2-5), melphalan (140 mg/m 2 , day 6)) chemotherapy with autologous stem cell support 2 days after the last day of chemotherapy. 6 The second intensification was to be administered within 8 weeks of the first intensification and consisted of the ICE regimen (ifosfamide 3 g/m 2 days 1-4, carboplatin 500 mg/m 2 days 1-3, etoposide 500 mg/m 2 days 1-3) with autologous stem cell reinfusion 3 days after the last day of chemotherapy. 7 Acyclovir was systematically administered starting on the day of stem cell reinjection and G-CSF was systematically administered beginning on the 8th day after reinfusion. Patients received intravenous heparin (100 IU/kg/day) for prophylaxis of VOD during the second intensification procedure.
Statistical methods:
Overall survival was defined as the time between the first course of treatment and death or last follow-up. Event-free survival (EFS) was defined as the time between the onset of treatment to the date of death, disease progression or last follow-up. Survival curves were calculated using the Kaplan-Meier method, and differences between them were tested for significance using the log-rank test. All statistical analyses were performed using Statistica software (Version 5.0, Statsoft, Tulsa, OK, USA).
Results
Patient characteristics (Table 1)
There were 17 females and 16 males. The median age was 38 years (15-59). Seventeen patients had two adverse prognostic factors of the International Prognostic Index (increased LDH, disseminated stage, poor performance status) and 16 patients had three adverse prognostic factors. The histological subtypes of NHL included diffuse large B cell lymphoma (20 patients), peripheral T cell lymphoma (four patients), lymphoblastic lymphoma (three patients), Burkitt lymphoma (three patients), anaplastic large cell lymphoma (two patients), transformed immunocytoma (one patient). All patients had disseminated disease. Seventy percent of the patients had extranodal disease, mainly in the liver and in serous effusions, and 33% patients had bone marrow involvement at diagnosis. Twelve patients had a performance status of 3 or 4. Thirty-one patients (94%) had increased serum LDH at diagnosis. Serum beta 2 microglobulin was significantly increased at diagnosis in 27% of patients and serum albumin was decreased in 54%.
Treatment administration
Induction therapy: Thirty-three patients were included in the protocol. Nine patients were treated at the first dose level, 11 at the second dose level, and 13 at the third dose level. Two patients received one course of ACE, seven patients received two courses and 24 patients received three courses. Two patients received only one course of ACE because of lethal tumor lysis syndrome (one patient) or progression (one patient). Among the seven patients having received two courses of ACE, two patients had disease progression, and five patients achieved complete response after two courses. Four of these proceeded directly to intensification, but one required additional chemotherapy (high-dose methotrexate) because of poor performance status before proceeding to intensification, 3. months after the beginning of therapy. The 24 patients who received three courses of ACE all proceeded to intensification. The median delay between courses 1 and 3 was 33 days, instead of a planned interval of 28 days. The main cause for delay during induction therapy was persistent thrombocytopenia at day 14. There were no dose reductions. The actual dose intensity/time in patients receiving three courses of ACE can thus be considered to be 85% of the planned value.
Stem cell collection:
A median number of 13 × 10 6 CD34
+ cells/kg were collected in 29 patients due to receive an autograft. All patients except one were collected in one series of cytaphereses, after the second course of ACE.
Consolidation therapy:
Overall 29 patients (88%) proceeded to high-dose therapy, including one patient for whom intensification was delayed. Four patients did not proceed to intensive therapy because of treatment failure during induction. A stem cell graft was obtained in all patients who were due to receive intensification. Seventeen patients (52% of the entire group) received only BEAM therapy and 12 patients (36% of entire group) received both BEAM and ICE regimens. The median interval between the first course of ACE and BEAM therapy was 59 days. The median interval between BEAM and ICE therapy was 80 days.
Toxicity Hematological toxicities and reconstitution:
All patients had grade 4 neutropenia after each course of ACE and 84% had grade 3-4 thrombocytopenia. Ninety-four per cent of the patients were hospitalized for febrile neutropenia after the first course, 66% after the second course and 54% after the third course. Infections during the induction and consolidation phases were unremarkable, consisting of gram-positive cocci and gram-negative bacilli, except for one patient who presented with CMV infection during induction, and another who presented with both Pneumocystis carinii and CMV infection during consolidation. There were no significant differences in hematological toxicity (data not shown) nor in the incidence of febrile aplasia (Table 2) between the different dose levels of ACE. The times to reach 100 and 500 polymorphonuclear cells/l after stem cell reinfusion were 9 and Table 2 Response rates and incidence of febrile aplasia according to treatment dose levels Leukemia 11 days, respectively, both after BEAM and after ICE. One patient had incomplete reconstitution after intensification, with persistent thrombocytopenia. The median total transfusion requirements during treatment (induction + consolidation) were three platelet transfusions (range 0-26), and 11 packed red blood cells (range 2-27).
Mucositis:
Twenty-five per cent of patients had grade 3-4 mucositis after induction therapy (with no significant differences between dose levels) and 73% of the patients required intravenous morphine for mucositis after BEAM therapy.
Toxic deaths:
There was one toxic death after the first course of ACE due to tumor lysis syndrome. There were no toxic deaths due to the intensification procedures. The overall toxic death rate was thus 3%.
Response to chemotherapy and survival
Response:
One patient died during the first course of ACE and was considered as a treatment failure. On an intent-totreat basis, 13 patients (39%) achieved complete remission at the end of induction treatment, with or without residual masses, and 16 patients achieved partial remission (49%). The overall response rate to induction therapy was thus 88% (95% confidence interval: 76-99%). Three patients were refractory to ACE induction therapy (9%). There was no significant difference in the response rates between the different dose levels of ACE (Table 2) .
Among the 28 patients who received intensive therapy according to the protocol, 16 were in partial response before high-dose treatment. These sixteen patients were evaluable for the response to the first course of high-dose therapy: 11 (69%) achieved CR with or without residual masses and five (31%) remained in partial response. The patient who underwent delayed intensification was in CR when she received BEAM therapy.
Among the five patients in PR after BEAM therapy, only two proceeded to ICE therapy, and did not achieve CR. On an intent-to-treat basis, the overall response rate after treatment completion was thus 88%, including 73% of CR (Figure 1 ).
Progression and survival:
In September 1999, the median follow-up for surviving patients was 29 months since the beginning of treatment (range 0-49 months). The overall survival (OS) and event-free survival (EFS) curves are shown in Figure 2 . There appears to be a survival 'plateau' at 71% (95% CI 64-78%), but three patients are currently alive in relapse. Nine patients (27%) have died: eight of progressive disease and one of tumor lysis syndrome. There were 12 events (36%): one fatal tumor lysis syndrome and 11 cases of disease progression.
Among the 11 cases (33%) of progressive disease, three patients had primary refractory disease and eight patients relapsed. The three primary refractory patients died 1.7, 2.3 and 6.2 months after the beginning of treatment. The five patients in partial response and three patients in complete response after high-dose therapy relapsed, after a median period of 11 months after the beginning of treatment (range 2-33 months). The three patients with lymphoblastic lymphoma relapsed, as well as two of the three patients with Burkitt's lymphoma.
Patients in complete response, with or without residual masses, after induction therapy had a better EFS than patients in partial response (P = 0.019, Figure 3 ) although the OS was not significantly different (data not shown). Patients who had not reached CR after intensification had shorter EFS (P = 0.0005, Figure 4 ) and shorter OS (P = 0.004, data not shown).
Figure 2
Overall survival (OS) and event-free survival (EFS) of NHL patients treated with the ACE protocol followed by intensification. Events included death and disease progression.
Discussion
Patients with NHL having two or more adverse prognostic factors at diagnosis have a lower chance of achieving complete response and being disease-free at 5 years than patients with 0 or 1 prognostic factor. The optimal first-line therapy of such poor risk patients remains controversial. The use of dose intensity has shown to increase response rate and survival in relapsing patients. [8] [9] [10] Various studies suggest that high-dose therapy, with or without stem cell support, of chemosensitive poor prognosis patients improves the percentage of patients achieving complete response as well as long-term survival. 4, [11] [12] [13] [14] [15] [16] However there are currently no prospective randomized trials which have confirmed the benefit of high-dose therapy as firstline treatment of poor risk NHL patients. 2 Our primary aim was to determine the feasibility of an intensified induction therapy yielding a high response rate in young poor risk NHL patients, followed by high-dose consolidation in chemosensitive patients. Various induction regimens derived from the original CHOP regimen have been evaluated in such patients, although alternate approaches incorporating etoposide have been used. 12, 17 In this trial we chose to increase the doses of the two most active compounds, doxorubicin and cyclophosphamide, in combination with etoposide, which has shown its efficacy both as first-line therapy and in relapsing NHL patients. 17, 18 Doxorubicin dose was limited to The only toxic death observed in the trial occurred on the first day of the first course in a patient who developed fatal tumor lysis syndrome, at the first dose level. Furthermore this regimen was adequate for stem cell collection, since cytaphereses were successful in all patients due to receive intensification. High-dose intensification was performed in 88% of the patients, as compared to 71% in the trial by Stahel et al 16 and 86% in the trial of Bouabdallah et al. 19 There were no toxic deaths due to the intensification procedure. Administration of the ACE regimen is feasible in young patients with poor prognosis aggressive NHL. It should be stressed however that patients included in this trial were not representative of all 'non-elderly patients' with aggressive lymphoma, since the median age was only 38 years.
The response rate to ACE induction therapy was high, with an overall response rate of 88% (including 39% of CR). In a Leukemia similar trial, Juliusson and Liliemark evaluated the CDE protocol containing high doses of cyclophosphamide and etoposide and obtained an overall response rate of 89% after two courses. 17 The response rate to BEAM therapy in the 16 evaluable patients was 69% as compared to 30% in 34 evaluable patients treated with high-dose busulfan/cyclophosphamide reported by Lee et al. 20 On an intent-to-treat basis, 24 patients (73%) had achieved CR at the end of treatment, which is comparable to rates observed by other investigators. 12, 19 The data suggest that intensification with BEAM contributed significantly to the favorable outcome of these high-risk patients, since half of the patients were in PR after induction therapy and all patients who had not reached CR after intensification underwent disease progression. It is however not possible to draw any conclusions on the benefit of the second intensification by ICE therapy in this limited series of patients. Overall in this poor risk group the combination of the dose-intensive ACE induction regimen and high-dose consolidation yielded a high rate of complete response.
Various investigators have analyzed the survival benefit of front-line high-dose therapy with stem cell support in high risk NHL patients. Literature data are often difficult to compare since many of the available studies have used different criteria to define high risk patients. Nademanee et al 21 administered high-dose cyclophosphamide, etoposide and TBI to high-risk NHL patients in first remission. These authors reported 3-year disease-free survival rates of 82% for the entire patient population, with a 60% rate in patients with small non-cleaved subtypes. Cortelazzo et al 22 have retrospectively compared two cohorts of patients treated with MACOP-B induction therapy, one of which received additional intensive therapy. The high-dose group tended to have a longer event-free survival, but the overall survival was not significantly different. 22 The 60% 3-year EFS survival rate observed in our group was similar to the 55% rate reported by Stahel et al 16 in high-risk patients treated with VACOP-B, followed by CBV intensification in first remission, and the 2-year 61% event-free survival observed by Pettengell et al 23 in patients receiving VAPEC-B induction followed by high-dose busulfan/ cyclophosphamide consolidation. It is possible that the current controversy regarding indications of intensification in poor risk patients with aggressive NHL stems at least partly from the fact that not only one but many issues remain to be clarified, including the type of prognostic factors present at diagnosis, the duration and nature of the induction regimen, and the quality of the response obtained after induction. The latter issue is of particular importance with recent improvements in the ability to detect residual tumor cells since highdose therapy is believed to be particularly useful in patients with clinical CR but subclinical disease.
In this study, patients with lymphoblastic and Burkitt's lymphoma displayed poor response to treatment, with an overall relapse rate of 83%, in spite of apparently satisfactory response to induction treatment. This is in contrast with data reported by Sweetenham et al 24, 25 which tended to show a benefit of high-dose therapy in chemosensitive patients with lymphoblastic or Burkitt's lymphoma. Although the number of patients with these subtypes was limited in our study, the ACE protocol followed by intensification should not be recommended in patients with high-grade lymphomas.
The currently available data suggest that early intensification of high risk NHL patients in first response increases EFS and overall survival. It is not yet clear whether high-dose therapy offers similar chances of survival to patients who do not reach CR after induction therapy, as has been suggested by various authors. 13, 20 In our series, in spite of the limited number of patients, we found that the EFS was better in patients who achieved CR after induction therapy, thereby highlighting the importance of an intensive induction therapy in high risk patients with aggressive NHL. These results also suggest that high-dose therapy might be particularly effective on residual disease. The ACE protocol is currently being compared to the less dose-intensive ACVB induction regimen 4 in the scope of a prospective randomized GELA trial (LNH 1998-3).
